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Iodium- I l-labeled antimyosin monoclonal antibody Fab is 
now used clinically for the noninvasive detection of myocar- 
dial damage that occurs in acute myocardial infarction (I-4). 
acute myocarditis (5,6) and cardiac rejection after cardiac 
transplantation (6-8). We recently reported (9) that iodine. 
lZU&led antimyosin Fab loulized releetively in the heart 
of mice with excerimental viral myocarditis and that a 
myocardial irna&io infected mice wai clearly obtained with 
iodine-13Llabekd antimyosin Fab. It is well known that the 
biodisiribotionofantibody changes by varying the radialabel 
001. The metallic radionuclide cf Indium-II I has been 
&eSted as a useful alternative to iodine-131 for the radio- 
label of monoclonal antibody for the following reasons: 
I) it has a lower energy (247 and 171 keV) than has 
iodine-131 (364 keV) but higher abundant photons: 2) there 
is a lack of high radiation beta particle emissions; 3) 
the physical half-life (2.83 days) is appropriate for anti- 
body imaging; and 4) dietbylenewkunine pentaace!ic acid- 
coqjugated antibodies can be labeled simply and rapidly with 
indium-ill (IO-l’& 
Thus, the pharmacokinetics and biodistribution of in- 
dium I I I-labeled antimyosin Fab were studied using marine 
viral-induced myocarditis as a model and compared with 
those of iodinelabeled antrmyosin antibody. Because many 
factors arc involved in the radioimmunodetection of myo- 
cardial damage, we extended this investigation to include the 
relation between myocardial uptake and pathologic grades 
and detect the presence of circulating antigen with high 
performance liquid chromatography. 
Methods 
AU experiments were petfonoed in accordance with the 
‘*Guidelines for Animal Hxperimenrs of Kyoto University.” 
ExperImental rlral myncarditis. A murine model of cn- 
cephalomyocarditis virus myocarditis was used (13). The 
Indium-Ill-labeled antlmyosin Farb imaging. The in- 
fcctcd mice on day 7 (n = 4) and uninfected mice (n = 3) 
virus stock was prepared as described previously (13) and 
had a titer OF I x LO7 plaque-forming unirslml determined in 
received an irdravenous injection of 70 $5 of indium-I II- 
labeled antlmvosin Fab. Mice were aneslhaized bv an 
tissue cultures of FL (human amnion) cells. It was stored al 
-70°C until use. Four week old male BALBlc mice were 
inoculated intraperironeally with a 0.1 ml encephaiomyo- 
carditis virus suspension conmining 100 plaque-forming 
units/ml. Age-malched BALB/c mice that were nor inocu- 
lated served as uninfected control mice. 
~~ralIon f indiufi~.lll-labeled aniimyaain monoclonal 
antibody. The antimyosin murine monoclonal antibody 
(RI lD10) was developed by Khaw et al. C 14) using a hybrid- 
oma technique. Indium-I I l-labeled antjmyosin Fab was 
prepared by papain digestion and coupled with diethylene- 
triamine Dentaacetic acid. a bifunctional chelatine acent 
(Daiichi iadioisotape Lab&tories Lid). Each mouse was 
injected intravenously with I.5 &i of indium-I 1 I-labeled 
antimyosin Fab through a tail vein for the biodisttibution. 
kinetic and pathologic correlation studies. In the imaging 
study, each mouse was injected intravenously with 70 pCi of 
indium-11 l-labeled antimyosin Fab. 
Biodh!xibulIen studieo. The seauential biodistribution of 
indium-Ill-labeled antimyosin in’infected mice on days 3 
(n = 9),S (n = 71, 7 (n - 30), 14 (n = 9). 21 (n = I I) and 28 
(n = 15) after inoculation of encephalomyocarditis virus and 
in each age-matched control mouse was studied, Twenty- 
four hours afier the injection of I .S pCi of indium-I 1 I-
lab&d amimyosin Fab, the mice were killed and their 
organs were excised. The heart, liver, kidneys, inresrine, 
stomach, spleen, lungs, skeletal muscle, skull, brain and 
pancreas were weighed, and tie uptake of the tracer was 
determined with a well-type autogamma counter. The tracer 
uptake was expressed as a percent of the injected dose per 
gram of organ (% injected dose/g) and as a ratio of percent 
dose per gram for the organ to prcent dose per milliliter for 
blwd (organ to blood ratio), The weight of the mice was 
normalized to 20 g. 
in vlvo !&et& The infected mice were killed on day 7 
after inoculation 3 (n = 6). 6 (n - 6). 12 (n = 61.24 (n = 61. 
36 (n = 6). 46 (n = 6) or 72 (n = 4 h after the intravenous 
injection of indium-II l-labeled antimyosin Fab. Myocardial 
uptake was determined and expressed as described in lhe 
biodistribution study. 
Pathologk correlation. After the biodistribution study, aI\ 
hearts were fixed in a 10% formalin sohuion. sectioned 
transversely at the midportion of the ventricle, embedded in 
pa&in and stained with hematoxy!in-cosio. Myocardial cell 
necrosis, cellular infiltration and calcification were scored 
blindly and independently by severity on a scale of 0 fo 3 
@adeO= > lesions; &nde I = lesions < 25% over rhe 
entire section; grade 2 = lesions between 25% and 50% ow.r 
the entire s&ion; and grade 3 = lesions > SO% over the 
entire section) (IS). 
intraperitoneai injecGonofpentobarbital(O.5 mg), and whole 
body images were obtained in the anterior view using a 
gamma camera (Pho-Gamma LFOV. Se&e) equipped with a 
pinhole collimator 48 h after administra!ion of the ra- 
diotrwer ion day 91. Fifty thousand counts were z~cumu- 
bated for whole body images af energy peaks of )7\ and 247 
keV using a 20% window. All scintigrams were interpreted 
indepetldently by two observers who were unaware of the 
experimental condhions. 
High performcc liquid chromato~flphy. High perfor- 
mance liquid chromatography wxth a TSX 03uoOSW size 
exclusion column (7.5 x 600 mrrd [Toyo-soda1 was used for 
the analysis of the injectate. serum samples from infected 
mice on day 7 In = 7) or age-matched uninfected mice (n = 
S). Serum samples were incubated in vitro with indium- I I I- 
labeled afltimyosin Fab for 3 h and !hen applied to the high 
performance liquid chromatography column. Borh the radic- 
acriviry and optical density at 280 nm were simultaneously 
measured. 
Statist&. Statistical comparisons were performed by 
analysis of variance (161. Results ate expressed as the mean 
value + SD. 
Resdts 
Bitdistributien rh: Q. The k.Iodistribufion of indium-1 I I- 
labeled antimyosin Fab in infected mice on day 7 and 
age-matched uninfected control mice 24 h after the adminis- 
tration of the radiotracer is shown in Figure 1. Only myo- 
cardial uptake increased signiticantly (p 4 0.001) in bOIh 5 
injecred dose/g organ and organ to blood ratio compared 
with va\~es in each coutrol mouse. In the other organ: 
(including the liver and kidneys). there was no signi:icant 
difference between the infected and the control mice. Hi& 
uptake by the liver and. kidneys was also demonstrated, 
whereas uptake by the intestine, stomach, spleen, lungs, 
muscle, skull. brainand pancreas was relatively low. Both % 
injected dose/g hean and the heart to blood ratio increased 
significantly in mix on days 5, 7 and I4 after inoculation 
with encephalomyocarditis virus compared with values in 
each iminfected control mouse (Fig. 21. There was a signif- 
icant difference between both % injected dose/g heart and 
the heart to blood ratio on day 7 (4.94 2 2.66 and 12.30 2 
7.63. respectively) and day 14 (2.21 + 0.6 and 7.67 L 3.8;. 
respectively). 
la viva kinetics study. Indium-Ill-labeled anttmyosin 
Fab was Cleared rapidly from the circulation (Fig. 3). Percent 
injected dose/g heart of infected mice vas highest at 3 h after 
Ihe injection of indium-I I I-labeled antimyorin Fab and then 
decreased gradually, whereas the heart to blood ratio in- 
Figure 1. The biodirtribulion ofindium-I I I (“‘In)_ 
labeled antimyorin Fab 24 h after :5e injection in 
encephalomyocardkis (EMC) virus-infected mice 
on day 7 after vims inoculation and uninfected 
age-matched control mice. 4. Percent injected 
dose (% I.D.) per gram organ. B, Ratio of percent 
dose per gram organ to percent dose per milliliter 
blood. Only the heart shows a significantly in- 
creased uptake of radiotracer compar d with either 
blood or corresponding organs in the conlrcl mice. 
Data represent Inran value. i SD. 
creased gradually until 48 h after administration of the Correlation belween mywardial uptake and pathologic 
radiotracer. largely related to a more gradual decrease in grades. Pathologic lesions were first noted in the myocw 
heart as compared with blood tracer concentration. Liver dium 5 days after the inoculation of encephdomyocarditis 
uptake was also intense and prolonged with time. virus. Myocardial necrosis was significantly prominent on 
davs 7 and 14 (Fig. 4). which was consistent wl:h ahe 
s&ential study of &cardial uptake of indium-I I I-labeled 
antimvosin Fab as alreadv described (Fk. 2). Cellular io!X 
tration was pA,ominent on days 7, 14 and 21 and calci6catiou 
was prominent at the i-& stage. Quantitative correlation 
between myocardial necrosis and myocardial up:?ke of 
indium-1 II-labeled antimyosin Fab was evaluated with use 
of infected mice on dav 7 (n = 30) and uninfect:d age- 
matched control mice (n = IO). The heart to blood ratio was 
4.30 -c 1.35 i:l uninfected mice Jnd 2.74 2 1.20 (wade 0: s : 
S), 10.47 i- 4 08 (grade I; n = 5), 14,:s L 6.95 (&ad: 2; n = 
13) and 30.71 -f 0.13 (grade 2; a * 2) in :nfec!G I+.:. 
Because the umber of mice with grade 3 involvement was 
small, we combined grade 3 and grade 2 for statistical 
analvsis of the hear1 to hlaoi! ratio (grade 2 plus grade 3 = 
16.7i + 7.32; n = IS). llle +.rt to blo?d iatii. of indium- 
Ill-labeled antimyc3in Fah LT:UI~ :. jed wail with paeologic 
grades of myacardial ncxo-is (FIN. . 
Mi~.lll-labeled.ananYmy&Fab .xmging. Positive im- 
caldltis wrus-mfecte< mice. However, mtrnse uptake m the 
liver and kidneys was observed in both infected and unin- 
fected nuce (Fig. 6). 
High performance liquid chromatography. Serum sari-- 
ples from the infected mice and uninfected mice were 
evaluated with aTSK G3ONlSW size exclusion column (Fig. 
7). A small radiolabeled peak at a molecular weight of SW to 
700 kd appsared in the serum from five of seyen infected 
mice, indicating the presence of an antigen-antibody corn- 
plex (Fig. 7A, arrow A), whereas no such peak was shown in 
the serum fmm uninfected mice (Fig. 78). A large iadiola- 
beled peak at a mo1ecul.u weight of 50 kd showed indium- 
Ill-labeled antimyosin Fab (Fig. 7A and B. arrow B). 
Discussion 
To detect myocardial damage noninvasively, indium-I1 I- 
labeled autimyosin monoclonal antibody Fab scintigraphy 
has oeen employed for clinical myocardiel imaging. How- 
ever. many factors such as rate and extent of antibody 
localization, kinetics, size of target organ (extent of cardiac 
lesion), metabolism of radiotracer (iodine or indium) and 
circulating zttigen (17,18) that can affect the imaging with 
radiolabeled antibodies (radioimmunodetection) have not 
been discussed. In this study, the biodistribution study of 
indium-I I l-labeled antimyosin Fab demonstrated increased 
myocwdial uptake in mice with acute experimental myo- 
carditis compared with uninfected control mice. In the 
imaging study, the cardiac lesion was clearly visualized in 
mice 7 days after encephelomyocarditis virus inoculation. 
Mium-Ill-labeled sntlmyesin Fah imaging. Although 
hiah sensitivitv in the detection of mvocardial damage bv 
i&urn-l I l-labeled autimyosin imagiw has been repot&i 
clinicallv (l-3.5.7). hieh uotake of in&m-Ill-labeled an- 
timyosin Fab wa6 bb&veb in the liver. In particular, high 
liver uptake may interfere with the visualization of inferior 
myocardial infarc:ion. In this study, liver uptake of indium. 
:I l-labeled antimyosin Fab was upproximately 2C :lmz~ as 
high as that of iodise-12Mubeied antimyosin Fah in a 
previous study (9j. ‘:his difference is considered to have 
occurred because: It transchelat,on of indium from diet!& 
enettiamine pentuucets acid to transfertin, which leads to 
high liver uptake because the liver has a large iron-binding 
capacity and the sequestration of indium occurs (17-19); and 
2) dchulogenation of iodine at the liver resulted in decreasing 
Figure 6. Representative color scintigram 
showing anterior whole body images of 
mice 24 h titer injection of 70 $I of 
indium-I I l-labeled antimyosin Fab. Spe- 
cihc uptake is seen at the cardiac lesion 
(ax-raw, of the infected mO”Je wtetlt,, but 
not in the uninfected mouse (let?). High 
uptake in the liver and the kidneys is also 
demonstrated. K = kidney; L = liver. 
liver uptake in the study using iodine-labeled antibody 
(17.20). 
Suitable imaging time v&s among studies U-8). In our 
study, the heart to blood ratio increased gradually after the 
injection of indium-II i-labeled antimyosin Fab and reached 
a maximum 48 h after the injection in the kinetics study. 
Johnson et al. (2) reported-that 31 of 39 @nar SC& 
performed 24 h after injection of tracer were di?;nostic in a 
&tlticenter clinical trial, although 8 (21%) showed persistent 
cardiac blood uool activitv that cleared bv 48 b. Carrio et al. 
(6) investigated the etTeft of residual csdiac blood poois 
using a cardiac to ittng tatio (antimyosin index). They 
rewted that the antimyosin indexes 24 h after the injection 
w&e signilicant~y greater than those 48 or 72 h after the 
iniection; there were no differences between the atttimyosin 
indexes 48 and 72 h after the iqjectiott in normal volunieers. 
Therefore, they decided that the 48 h antimyosin index was 
suitable in the evaluation of patients with suspected myo- 
carditis or cardiac transplantation. These results and ours 
indicate that the optimal time of indium-II I-labeled antimy- 
osin xintigraphy may be 48 h after injection. 
Antlmyosln Feb antigeuatllbody complex. High pet-for- 
mance liquid chmmatogmphy of the serum from infected 
mice demonstrated radioactivity et a molecular weight of500 
to 700 kd. This was considered to be an antigen-antibody 
complex in which the molecular weight of the antigen was 
expected to be between 450 and 650 kd because the mokc- 
ular weight of antimvosin Fab is 50 kd and that of transfenin 
is 90 kd:Theref*re,.tnnsehelaled indium-i I from diethyl- 
ssztriamioe pa-&acetic acid to trmtsfemn could be hidden 
in the radiolabeled peak of indium-ill-labeled antimyosin 
Fab. Whole myosin (molecular weight 5Q0 kd) consists of 
two components, that is, four subunits of light chains (mo- 
lec~lar weigltt 20 kd) and two subunits of heavy chains 
(m&cular weight 2Ml kd). It has been repotled (21-23) that 
myasin components are shed into the circulation system 
from the domaged myocardium in myocardii infarction. 
L 
However, from our high performance liquid chmmatogmphy 
analysis, this antigen bound to the antibody in the circulation 
might not be a my& component and instead be whole 
myosin itself. This antigen-antibody complex formation has 
been observed (18,24-X) to decrease the uptake in the 
target organ and increase the incorporation in !he hver and 
spleen. Thus, a high level of circulating antigen may some- 
times interfere with imaging of the heart. 
Pathologic cwrel&ms. We demonstrated that myocw 
dial uptake of indium-I I I&b&d antimyosin Fah in infected 
mice correlated well with the extent of necrotic lesions 
induced by the encepitalomyocdrditis virus. In clinical stod- 
ies, quatttrtative stimation was performed by Carrio et al. 
(6) between the antimyosin index and biopsy scores of 
endomyocardial biopsy specimens. They found significant 
correlations between antimyosin indexes and cardiac rejec- 
tion. 
Conclusions. Myocardial uptake of indium-I I l-labeled 
antimyosin Fab varies with the-degree ofmyocardial damage 
and imaging time. Indittm-l I I-labeled antimyosin F&b local- 
izes selectively in the mut’inc hart of encephalomyocarii.~; 
virus-induced myocxdiris. Although indium-I I I-labeled an- 
:i:nyosfn Fab scintigraphy is no’ srcific fcr viwt myocardi- 
tis, it may be a useful method for the detection and assess- 
ment of mywwdial necrosis in myocarditis. 
L. 
&we ‘I. Representative high performance liquid chromato~~~hy 
of the serum from virus-infected and uninfected mice. Radmactivity 
revealed an antlgcn~antibody comptcx of myorin and indium-Ill 
(“‘InI-taheled antimyosin Fab in the semm born infected mice 
(arrow A in 4): hut not in the senmt from uninfected mice IB). a = 
void volume llmmunoglobulin M; molecular weight !SQ kdl, b = 
alpha,-macroglobulin (molecular weight 725 kd). c = immunogtob- 
ulin G (molw~lar weight 150 kd). d = albumin 6nalcculxveight 69 
Cd). B = indium-Ill lab&C antimyosin Fab (injectate: melecular 
weight 50 kdl; ,wlid line = radioactivity; bmhn tine = optical 
density ,OD, at Xl “In. 
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